Category - Markets

Markets

Athersys prices $20-million stock offering

Athersys (NASDAQ:ATHX) priced a public offering of 19,802,000 common shares at a price of $1.01 each for gross proceeds of about $20-million and gave underwriters an option to purchase up to an additional 2,970,300...

January 27, 2017

Markets

Feltl ups Heska price target to $97

Feltl reiterated a “strong buy” rating for Heska (NASDAQ:HSKA) and raised its price target to $97 from $67 on an increased valuation multiple reflecting Heska’s improved positioning. The stock was quoted at $76.46 near...

January 26, 2017

Markets

Maxim upgrades ADMA Biologics to buy

Maxim Group upgraded ADMA Biologics (NASDAQ:ADMA) to ‘buy” from “hold” and established a price target of $13 after the company agreed to acquire Biotest Pharmaceuticals’ immunoglobulin manufacturing facility in Florida...

January 24, 2017

Markets

Roth resumes coverage of Palatin, AmpliPhi, Pharming

Roth Capital Partners resumed coverage of Palatin Technologies (NYSE MKT: PTN), AmpliPhi Biosciences (NYSE MKT:APHB) and Pharming Group NV (OTC:PHGUF) with “buy” ratings and price targets of $1.50, $3 and €1.50...

January 24, 2017

Markets

HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20. Bellerophon develops products for the treatment of...

January 23, 2017

Markets

HCW starts Trevena at buy

H.C. Wainwright initiated coverage of Trevena (NASDAQ:TRVN) with a “buy” rating and $11 price target. The shares were changing hands at $6.85 at mid-day on Jan. 9. “We believe Trevena’s lead drug, oliceridine...

January 9, 2017

Markets

Canaccord starts Natera at buy

Canaccord Genuity initiated coverage of Natera (NASDAQ:NTRA) with a “buy” rating and $18 price target. The stock is changing hands at $11.66 in afternoon trading on Jan. 6. Natera is the market leader in the $2.5...

January 6, 2017

Markets

HCW starts Calithera Biosciences at buy

H.C. Wainwright initiated coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $9 price target. The stock closed at $3.95 on Jan. 5. Calithera is developing oral drugs that target feeding of cancer...

January 6, 2017

Markets

Leerink starts Achaogen at outperform

Leerink initiated coverage of Achaogen (NASDAQ:AKAO) with an “outperform” rating and $21 price target. The shares were changing hands at $13.90 in afternoon trading on Jan. 4. Achaogen is developing lead product...

January 4, 2017

Markets

Ladenburg upgrades Codexis to buy

Ladenburg Thalmann upgraded Codexis (NASDAQ:CDXS) to “buy” from “neutral” with a new price target of $6.25. The shares were quoted at $4.65 in afternoon trading on Jan. 4. Analyst Kevin DeGeeter cited growing confidence...

January 4, 2017

Category - Markets

Subscribe